We live in an era of specialty pharmaceuticals — drugs typically used to treat chronic, serious or life threatening conditions such as cancer, rheumatoid arthritis, growth hormone deficiency, and multiple sclerosis. Their cost is often much higher than traditional drugs, and they are set to account for more than half of all drug spending by the end of this decade.
The October 2014 edition of Health Affairs, “Specialty Pharmaceutical Spending and Policy,” contains a cluster of articles examining the host of issues related to specialty pharmaceuticals: from the promise they hold for curing or managing chronic diseases, to the risk they pose for exacerbating health care costs and disparities, and the challenges they present for policymakers striving to balance both.
Please join us on Tuesday, October 7, for a briefing on the October issue moderated by Health Affairs Editor-in-Chief Alan Weil.
Tuesday, October 7, 2014
9:00 a.m. – 11:30 a.m.
Hyatt Regency Capitol Hill
400 New Jersey Avenue, NW
Washington, DC, Lower Level
Follow Live Tweets from the briefing @Health_Affairs, and join in the conversation with #HA_SpecialtyDrugs.
Health Affairs is grateful to CVS Health for its financial support of the issue and event.
Read the rest of this entry »